Van Dang, D.V.M., Ph.D., Abhi Saharia, Ph. D., and Audrey Bergeron, Applications Scientist
Chimeric antigen receptor (CAR)-T cells, which are engineered to recognize target cell surface antigens expressed on tumor cells, have shown promise to affect complete remission in patients with B-cell malignancies. However, applying this approach to target solid tumors has resulted in adverse effects in clinical studies. Methods for testing different models of CAR-T cells in vitro can provide further insight into viable antigen targets. Historically, two-dimensional (2D) cell culture models have been used in drug discovery. However, more elaborate, three-dimensional (3D) cell culture models better mimic the in vivo tumor microenvironment and help bridge the gap between in vitro studies and clinical outcomes.
Conventional methods for 3D cell culture are often time consuming, display increased variability and lack throughput. Here, we present data on a high-throughput, easy-to-use, highly reproducible method for screening CAR-T cells in a 3D cell culture model by combining various technologies. In this webinar, we will present data from ProMab Biotechnologies, DiscoverX, and Corning Life Sciences that together address these specific challenges and enable a high throughput CAR-T cell screening assay that targets tumor spheroids.
Van Dang, D.V.M., Ph.D.
Scientist and coordinator for CAR-T research
ProMab Biotechnologies, Inc.
Abhi Saharia, Ph. D.
Director, Cell-based Assays and Biologics
Corning Life Sciences